Smeland Knut Bjøro, Kiserud Cecilie E, Lauritzsen Grete F, Blystad Anne Kirsti, Fagerli Unn Merete, Fluge Øystein, Fosså Alexander, Hammerstrøm Jens, Kolstad Arne, Loge Jon Håvard, Maisenhølder Martin, Østenstad Bjørn, Kvaløy Stein, Holte Harald
Tidsskr Nor Laegeforen. 2013 Sep 3;133(16):1704-9. doi: 10.4045/tidsskr.13.0243.
High-dose therapy with autologous stem cell support (HDT) has been a treatment option for lymphomas in Norway for 25 years. The purpose of the article was to describe the use of the therapy for lymphomas for the country as a whole and by health region, and to reveal the overall survival rate.
All lymphoma patients ≥ 18 years who received HDT in Norway in the period 1987-2008 are included. Patients, diagnostics and treatment are identified for each hospital. Data for the population base have been retrieved from Statistics Norway.
Altogether 726 lymphoma patients received HDT in Norway in the period 1987-2008, with an annual average of 0.72 per 100,000 inhabitants. The annual number of treatments increased until 2004 and has since been stable. The average number of treatments per 100,000 inhabitants per year was 0.94 for Northern Norway Health Region, 0.80 for South-Eastern Norway Health Region, 0.58 for Central Norway Health Region and 0.55 for Western Norway Health Region. Early mortality (death within 100 days) was 6%. Ten-year overall survival was 55% (95% CI 51-59%), and Hodgkin's lymphoma had the best survival of the lymphoma groups (p = 0.01).
The annual number of HDT increased gradually until 2004. The use of the treatment varied according to the patients' place of residence at the time of diagnosis, and was most frequently used for patients belonging to Northern Norway Health Region. More than half of the lymphoma patients are alive ten years after the treatment.
在挪威，采用自体干细胞支持的大剂量疗法（HDT）治疗淋巴瘤已有25年。本文旨在描述该疗法在挪威全国及各健康区域治疗淋巴瘤的使用情况，并揭示总生存率。
纳入1987年至2008年期间在挪威接受HDT治疗的所有≥18岁淋巴瘤患者。确定每家医院的患者、诊断和治疗情况。人口基数数据取自挪威统计局。
1987年至2008年期间，挪威共有726例淋巴瘤患者接受了HDT治疗，平均每年每10万居民中有0.72例。治疗的年数量在2004年之前增加，此后一直稳定。挪威北部健康区域每年每10万居民的平均治疗次数为0.94次，挪威东南部健康区域为0.80次，挪威中部健康区域为0.58次，挪威西部健康区域为0.55次。早期死亡率（100天内死亡）为6%。十年总生存率为55%（95%可信区间51 - 59%），霍奇金淋巴瘤在淋巴瘤组中生存率最佳（p = 0.01）。
HDT的年数量在2004年之前逐渐增加。治疗的使用因患者诊断时的居住地点而异，在挪威北部健康区域的患者中使用最为频繁。超过一半的淋巴瘤患者在治疗十年后仍然存活。
